arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Acrivon Therapeutics, Inc.

ACRV

$2.05 ▼ -0.10 (-4.43%) at close

6 Visible periods

19 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Acrivon Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $78.9M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -74.8% ↘

FCF / Share $-1.70 ↗

Trailing P/E —

Price / Book 0.6x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Sep 23, 2026.

6-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-77.91M

↑ +3.3% —

FCF / Share Free cash flow per share

$-1.70

↑ +16.2% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Cash Quality →

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
EPS Growth YoY (%)	15.1% Good ↓ Good Declining Year-over-year change in earnings per share Optimal: > 10%	13.1% Fair ↓ Fair Declining Year-over-year change in earnings per share Optimal: > 10%	63.8% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	18.9% Good Good Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	3.3% Caution ↑ Caution Improving Year-over-year change in net income	-33.4% Weak ↑ Weak Improving Year-over-year change in net income	-93.8% Weak Weak Year-over-year change in net income	-91.9% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	16.2% Good ↓ Good Declining Year-over-year change in free cash flow	-1.8% Weak ↓ Weak Declining Year-over-year change in free cash flow	74.6% Excellent Excellent Year-over-year change in free cash flow	4.0% Caution Caution Year-over-year change in free cash flow	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Effective Tax Rate (%) (%)	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—	—	—
FCF / Net Income (x)	0.84x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.85x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.73x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.04x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	0.88x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Return on Invested Capital (%)	-74.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-39.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-43.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-15.1% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	53.7% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-64.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-45.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-48.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-18.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	-15.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-69.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-562%)	-45.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-404%)	-49.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-432%)	-18.3% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-222%)	68.2% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+355%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Net Debt (USD)	$-41.50M	$-39.82M	$-36.02M	$-29.52M	$-99.60M	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Basic EPS, GAAP (USD)	$-2.02	$-2.38	$-2.74	$-7.56	$-9.32	—
Free Cash Flow per Share (USD)	$-1.70	$-2.03	$-1.99	$-7.83	$-8.16	—
Book Value per Share (USD)	$3.56	$5.66	$5.38	$7.78	$-13.45	—
Tangible Book Value per Share (USD)	$3.56	$5.66	$5.38	$7.78	$-13.45	—
Basic Weighted Avg Shares (shares)	38.51M	33.79M	22.08M	4.12M	1.74M	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Working Capital (USD)	$104.78M	$164.41M	$116.39M	$125.58M	$97.49M	—
Total Equity (USD)	$112.52M	$176.79M	$121.19M	$170.47M	$-23.81M	$-8.41M

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Depreciation Expense (USD)	$1.36M	$1.01M	$536.00K	$364.00K	$37.00K	—
Net Income, GAAP (USD)	$-77.91M	$-80.56M	$-60.39M	$-31.17M	$-16.24M	—
Operating Cash Flow (USD)	$-63.66M	$-65.67M	$-42.64M	$-30.12M	$-13.98M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 6 years · 23 quarters

Acrivon Therapeutics, Inc.

Analytical Summary

6-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare ACRV with peers